Cogent Biosciences rises as bezuclastinib FDA filings near and ASCO catalyst approaches
Cogent Biosciences shares are higher as investors position ahead of near-term FDA filing milestones for bezuclastinib, including a GIST NDA completion targeted for April 2026 and additional submissions in 1H 2026. Recent momentum has also been supported by the company’s April 21, 2026 update that Phase 3 PEAK data will be presented orally at ASCO (May 29–June 2, 2026).
1. What’s moving the stock
Cogent Biosciences (COGT) is trading higher today as the market focuses on its 2026 regulatory runway for bezuclastinib and the next set of scheduled catalysts. The company has laid out a sequence of FDA submissions, including a second-line GIST NDA completion targeted for April 2026 and an additional NDA planned in the first half of 2026, keeping the name in a “catalyst window” that often drives incremental buying on quiet news days. (investors.cogentbio.com)
2. The most recent fundamental catalyst in the tape
The latest company-driven headline still resonating in the stock is the April 21, 2026 announcement that results from the Phase 3 PEAK trial in GIST were selected for an oral presentation at the 2026 ASCO Annual Meeting in Chicago (May 29–June 2, 2026). Oral presentations are typically viewed as higher-profile visibility versus posters, and traders often position ahead of major conference readouts even when the detailed dataset is not yet released. (globenewswire.com)
3. What investors are watching next
Beyond ASCO, attention remains on the bezuclastinib regulatory timeline that has already advanced with an NDA submission for nonadvanced systemic mastocytosis and the broader plan for multiple filings. The key question for the next leg in the stock is whether the GIST submission has been completed (or acknowledged by the FDA) and how quickly review timelines crystallize as the company progresses through its planned first-half 2026 filings. (investors.cogentbio.com)
4. Near-term calendar risk
COGT also has a near-term trading catalyst with its next quarterly results expected soon (with broad market calendars pointing to early May). With biotech stocks, pre-earnings positioning can add volatility even if the primary driver remains pipeline and regulatory milestones, particularly when major clinical and FDA events are in view. (marketbeat.com)